Market Update: Gilead Sciences Inc (NASDAQ:GILD) – European Medicines Agency Validates Gilead’s Marketing Application for Single Tablet Regimen Containing Rilpivirine, Emtricitabine and Tenofovir Alafenamide (R/F/TAF) for HIV Treatment

[Business Wire] – Gilead Sciences, Inc. today announced that the company’s Marketing Authorization Application for an investigational, once-daily single tablet regimen that combines emtricitabine 200 mg, tenofovir alafenamide 25 mg and rilpivirine 25 . . . → Read More: Market Update: Gilead Sciences Inc (NASDAQ:GILD) – European Medicines Agency Validates Gilead’s Marketing Application for Single Tablet Regimen Containing Rilpivirine, Emtricitabine and Tenofovir Alafenamide (R/F/TAF) for HIV Treatment Similar Articles: Company Update (NASDAQ:GILD): Gilead Sciences to Release Second Quarter 2015 Financial Results on Tuesday, July 28, 2015 Market Update (NASDAQ:GILD): Gilead Sciences to Present at the UBS 2015 Global Healthcare Conference on Tuesday, May 19 Company Update: Gilead Sciences Inc (NASDAQ:GILD) – Gilead Sciences to Present at the Barclays Global Healthcare Conference on Wednesday, March 11